Roghayeh Zare1, Azadeh Nadjarzadeh2, Mohammad Mehdi Zarshenas3, Mesbah Shams4, Mojtaba Heydari5. 1. Department of Persian Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Persian Medicine, Faculty of Persian Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 2. Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 3. Department of Phyopharmaceuticals (Traditional Pharmacy), School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; Medicinal Plants Processing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 4. Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 5. Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: mheydari@sums.ac.ir.
Abstract
BACKGROUND & AIMS: Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results. Differences in Baseline Body Mass Index (BMI) of patients may be able to explain the observed differences in the results. This study was designed to evaluate the effect of cinnamon supplementation on anthropometric, glycemic and lipid outcomes of patients with DM type II based on their baseline BMI. METHODS: The study was designed as a triple-blind placebo-controlled randomized clinical trial, using a parallel design. One hundred and forty patients referred to Diabetes Clinic of Yazd University of Medical Sciences with diagnosis of DM type II were randomly assigned in four groups: cinnamon (BMI ≥ 27, BMI < 27) and Placebo (BMI ≥ 27, BMI < 27). Patients received cinnamon bark powder or placebo in 500 mg capsules twice daily for 3 months. Anthropometric, glycemic and lipid outcomes were measured before and after the intervention. RESULT: Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level). All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27). CONCLUSION: Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes. These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27). The trial protocol was registered in Iranian Registry of Clinical Trials database (registration ID: IRCT2017031133015N1).
RCT Entities:
BACKGROUND & AIMS: Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results. Differences in Baseline Body Mass Index (BMI) of patients may be able to explain the observed differences in the results. This study was designed to evaluate the effect of cinnamon supplementation on anthropometric, glycemic and lipid outcomes of patients with DM type II based on their baseline BMI. METHODS: The study was designed as a triple-blind placebo-controlled randomized clinical trial, using a parallel design. One hundred and forty patients referred to Diabetes Clinic of Yazd University of Medical Sciences with diagnosis of DM type II were randomly assigned in four groups: cinnamon (BMI ≥ 27, BMI < 27) and Placebo (BMI ≥ 27, BMI < 27). Patients received cinnamon bark powder or placebo in 500 mg capsules twice daily for 3 months. Anthropometric, glycemic and lipid outcomes were measured before and after the intervention. RESULT: Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level). All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27). CONCLUSION: Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes. These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27). The trial protocol was registered in Iranian Registry of Clinical Trials database (registration ID: IRCT2017031133015N1).
Authors: Kaushik Chattopadhyay; Haiquan Wang; Jaspreet Kaur; Gamze Nalbant; Abdullah Almaqhawi; Burak Kundakci; Jeemon Panniyammakal; Michael Heinrich; Sarah Anne Lewis; Sheila Margaret Greenfield; Nikhil Tandon; Tuhin Kanti Biswas; Sanjay Kinra; Jo Leonardi-Bee Journal: Front Pharmacol Date: 2022-06-08 Impact factor: 5.988
Authors: Rabia Shabir Ahmad; Muhammad Bilal Hussain; Muhammad Tauseef Sultan; Muhammad Sajid Arshad; Marwa Waheed; Mohammad Ali Shariati; Sergey Plygun; Mohammad Hashem Hashempur Journal: Evid Based Complement Alternat Med Date: 2020-05-10 Impact factor: 2.629
Authors: Nasra Ayuob; Mona Ramadan Al-Shathly; Abdulaziz Bakhshwin; Nouf Saeed Al-Abbas; Nehad A Shaer; Soad Al Jaouni; Walaa H E Hamed Journal: Front Pharmacol Date: 2021-05-13 Impact factor: 5.810